

Buchanan D, Miller FG (2005). Principles of early stopping of randomized trials for efficacy: A critique of equipoise and an alternative nonexploitation ethical framework. *Kennedy Institute of Ethics Journal* **15**: 161-178.

Conner EM, Sperling RS, Gelber R, et al., for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group (1994). Reduction of maternal-infant transmission of human immunodeficiency virus Type 1 with Zidovudine treatment. *New England Journal of Medicine* **331**:1173-1180.

DeMets DL, Furberg CD, Friedman LM (2006). *Data Monitoring in Clinical Trials: A Case Studies Approach*. Springer, New York, NY.

Ellenberg SS, Fleming TR, DeMets DL (2002). *Data Monitoring Committees in Clinical Trials: A Practical Perspective*. John Wiley & Sons.

Gordon VM, Sugarman J, Kass N (1998). Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials. *IRB: A Review of Human Subjects Research*. **20**: 1-5.

Hibberd PL, Weiner DL (2004). Monitoring participant safety in phase I and II interventional trials: options and controversies. *J Investig Med* **52**: 446-52.

SCT Working Group on Data Monitoring. Dixon DO, Freedman RS, Herson J, et al. (2006). Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees. *Clinical Trials* **3**: 314-319.

U.S. Food and Drug Administration (2006). Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees. <http://www.fda.gov/cber/gdlins/clintrialdmc.htm> (accessed January 3, 2008).

Wittes J, Barrett-Connor E, Braunwald E, et al. (2007). Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board. *Clinical Trials* **4**: 218-234.